{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:52:53Z","timestamp":1768823573467,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Complex high-precision radiotherapy, such as stereotactic body radiotherapy (SBRT), should only be offered to patients with sufficiently long survival. In the context of bone metastases radiotherapy, low rates of treatment close to the end of life, e.g. last 30\u00a0days (RT30), may serve as a quality of care indicator. While traditional, pain-relieving short-course regimens have been studied comprehensively, real-world SBRT results are still limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis (2010\u20132023, n\u2009=\u20091117 episodes) of patients with bone metastases treated with traditional single-fraction (8\u00a0Gy\u2009\u00d7\u20091) or multi-fraction regimens (often 4\u00a0Gy\u2009\u00d7\u20095 or 3\u00a0Gy\u2009\u00d7\u200910) compared to stereotactic single-fraction (12\u201316\u00a0Gy\u2009\u00d7\u20091) or multi-fraction regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Except for gender, almost all baseline variables were uneven distributed. Failure to complete fractionated radiotherapy was uncommon in the stereotactic (4%) and non-stereotactic group (3%), <jats:italic>p<\/jats:italic>\u2009=\u20091.0. With regard to RT30, relevant differences emerged (19% for 8-Gy single-fraction versus 0% for stereotactic single-fraction, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). The corresponding figures were 11% for multi-fraction non-stereotactic and 2% for multi-fraction stereotactic, <jats:italic>p<\/jats:italic>\u2009=\u20090.08. Median overall survival was shortest after 8-Gy single-fraction irradiation (4.2\u00a0months) and longest after stereotactic multi-fraction treatment (13.9\u00a0months). Neither stereotactic radiotherapy nor multi-fraction treatment improved survival in multivariate Cox regression analysis. Factors significantly associated with longer survival included better performance status, lower LabBM score (5 standard blood test results), stable disease outside of irradiated area(s), metachronous distant metastases, longer time interval from metastatic disease to bone irradiation, and outpatient status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The implementation of SBRT for selected patients has resulted in low rates of non-completion and RT30. Optimal selection criteria remain to be determined, but in current clinical practice we exclude patients with poor performance status, unfavorable blood test results (high LabBM score) and progressive disease sites not amenable to SBRT. Established, guideline-endorsed short-course regimens, especially 8-Gy single-fraction treatment, continue to represent an important palliative approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-024-02547-x","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:02:13Z","timestamp":1730462533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic radiotherapy for patients with bone metastases: a selected group with low rate of radiation treatment during the last month of life?"],"prefix":"10.1186","volume":"19","author":[{"given":"Carsten","family":"Nieder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellinor C.","family":"Haukland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e5rd","family":"Manns\u00e5ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2547_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.semradonc.2023.07.001","volume":"33","author":"M Yan","year":"2023","unstructured":"Yan M, Abdel-Rahman F, Dawson L, Wong P, Wong RKS, Tsai CJ. Advances and challenges in trials of local therapy for patients with oligometastatic or oligoprogressive disease. Semin Radiat Oncol. 2023;33:416\u201328.","journal-title":"Semin Radiat Oncol"},{"key":"2547_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semradonc.2022.11.006","volume":"33","author":"M Guckenberger","year":"2023","unstructured":"Guckenberger M, Dahele M, Ong WL, Sahgal A. Stereotactic body radiation therapy for spinal metastases: Benefits and limitations. Semin Radiat Oncol. 2023;33:159\u201371.","journal-title":"Semin Radiat Oncol"},{"key":"2547_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden J, Willmann J, Spa\u0142ek M, Oldenburger E, Brown S, Kazmierska J, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022;173:197\u2013206.","journal-title":"Radiother Oncol"},{"key":"2547_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1748-717X-8-85","volume":"8","author":"C Nieder","year":"2013","unstructured":"Nieder C, Pawinski A, Dalhaug A. Continuous controversy about radiation oncologists\u2019 choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies? Radiat Oncol. 2013;8:85.","journal-title":"Radiat Oncol"},{"key":"2547_CR5","doi-asserted-by":"publisher","first-page":"109914","DOI":"10.1016\/j.radonc.2023.109914","volume":"189","author":"HC Wong","year":"2023","unstructured":"Wong HC, Lee SF, Chan AW, Caini S, Hoskin P, Simone CB, et al. Stereotactic body radiation therapy versus conventional external beam radiotherapy for spinal metastases: a systematic review and meta-analysis of randomized controlled trials. Radiother Oncol. 2023;189:109914.","journal-title":"Radiother Oncol"},{"key":"2547_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13014-022-02128-w","volume":"17","author":"K Ito","year":"2022","unstructured":"Ito K, Saito T, Nakamura N, Imano N, Hoskin P. Stereotactic body radiotherapy versus conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis of randomised controlled trials. Radiat Oncol. 2022;17:156.","journal-title":"Radiat Oncol"},{"key":"2547_CR7","first-page":"75","volume":"25","author":"EF Gillespie","year":"2020","unstructured":"Gillespie EF, Lapen K, Wang DG, Wijetunga N, Pastrana GL, Kollmeier MA, et al. Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: a large multi-site single institution experience 2016\u20132018. Clin Transl Radiat Oncol. 2020;25:75\u201380.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2547_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2021;22:1023\u201333.","journal-title":"Lancet Oncol"},{"key":"2547_CR9","doi-asserted-by":"crossref","unstructured":"Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: A randomized phase 2 trial. JAMA Oncol. 2019;5:872\u20138. Erratum in: JAMA Oncol. 2021;7:1581.","DOI":"10.1001\/jamaoncol.2019.0192"},{"key":"2547_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jnci\/djz101","volume":"111","author":"KL Spencer","year":"2019","unstructured":"Spencer KL, van der Velden JM, Wong E, Seravalli E, Sahgal A, Chow E, et al. Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst. 2019;111:1023\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"2547_CR11","doi-asserted-by":"crossref","unstructured":"Vilotte F, Pasquier D, Blanchard P, Supiot S, Khalifa J, Schick U, et al. Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey. Clin Transl Radiat Oncol. 2022;37:33\u201340.","DOI":"10.1016\/j.ctro.2022.08.006"},{"key":"2547_CR12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2022.07.003","volume":"114","author":"I Madani","year":"2022","unstructured":"Madani I, Sahgal A, Erler D, Stish BJ, Olivier KR, Park SS, et al. Stereotactic body radiation therapy for metastases in long bones. Int J Radiat Oncol Biol Phys. 2022;114:738\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2547_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13:96.","journal-title":"Radiat Oncol"},{"key":"2547_CR14","doi-asserted-by":"publisher","first-page":"1270080","DOI":"10.1080\/22423982.2016.1270080","volume":"76","author":"C Nieder","year":"2017","unstructured":"Nieder C, Dalhaug A, Haukland E, Manns\u00e5ker B, Pawinski A. Contemporary radiooncological management of bone metastases from breast cancer: factors associated with prescription of different fractionation regimens (short or long course) in a rural part of North Norway with long travel distance. Int J Circumpolar Health. 2017;76:1270080.","journal-title":"Int J Circumpolar Health"},{"key":"2547_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.5603\/RPOR.a2021.0096","volume":"26","author":"C Nieder","year":"2021","unstructured":"Nieder C, Dalhaug A, Haukland E. The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy. Rep Pract Oncol Radiother. 2021;26:740\u20136.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2547_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/COC.0000000000000987","volume":"46","author":"C Nieder","year":"2023","unstructured":"Nieder C, Haukland EC, Manns\u00e5ker B, Dalhaug A. The LabPS score: inexpensive, fast, and site-agnostic survival prediction. Am J Clin Oncol. 2023;46:178\u201382.","journal-title":"Am J Clin Oncol"},{"key":"2547_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13014-023-02253-0","volume":"18","author":"C Nieder","year":"2023","unstructured":"Nieder C, Stanisavljevic L, Manns\u00e5ker B, Haukland EC. Early death after palliative radiation treatment: 30-, 35- and 40-day mortality data and statistically robust predictors. Radiat Oncol. 2023;18:59.","journal-title":"Radiat Oncol"},{"key":"2547_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","volume":"39","author":"DC McMillan","year":"2013","unstructured":"McMillan DC. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534\u201340.","journal-title":"Cancer Treat Rev"},{"key":"2547_CR19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/neuonc\/nox054","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, et al. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol. 2017;19:1255\u201362.","journal-title":"Neuro Oncol"},{"key":"2547_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00066-022-02040-y","volume":"199","author":"C Nieder","year":"2023","unstructured":"Nieder C, Haukland EC, Manns\u00e5ker B, Dalhaug A. Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation. Strahlenther Onkol. 2023;199:278\u201383.","journal-title":"Strahlenther Onkol"},{"key":"2547_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/jpm.2022.0173","volume":"26","author":"JC Farris","year":"2023","unstructured":"Farris JC, Johnson AG, Carriere PP, Patel ZA, Nagatsuka M, Farris MK, et al. Palliative appropriateness criteria: a pragmatic method to evaluate the suitability of palliative radiotherapy fractionation. J Palliat Med. 2023;26:67\u201372.","journal-title":"J Palliat Med"},{"key":"2547_CR22","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/cncr.34626","volume":"129","author":"RO Kowalchuk","year":"2023","unstructured":"Kowalchuk RO, Mullikin TC, Florez M, De BS, Spears GM, Rose PS, et al. Development and validation of a recursive partitioning analysis-based pretreatment decision-making tool identifying ideal candidates for spine stereotactic body radiation therapy. Cancer. 2023;129:956\u201365.","journal-title":"Cancer"},{"key":"2547_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/neuros\/nyaa583","volume":"88","author":"KL Zeng","year":"2021","unstructured":"Zeng KL, Sahgal A, Tseng CL, Myrehaug S, Soliman H, Detsky J, et al. Prognostic factors associated with surviving less than 3 months vs greater than 3 years specific to spine stereotactic body radiotherapy and late adverse events. Neurosurgery. 2021;88:971\u20139.","journal-title":"Neurosurgery"},{"key":"2547_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaoncol.2023.0356","volume":"9","author":"S Ryu","year":"2023","unstructured":"Ryu S, Deshmukh S, Timmerman RD, Movsas B, Gerszten P, Yin FF, et al. Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG Oncology\/RTOG 0631 randomized clinical trial. JAMA Oncol. 2023;9:800\u20137.","journal-title":"JAMA Oncol"},{"key":"2547_CR25","first-page":"26","volume":"30","author":"SM Christ","year":"2021","unstructured":"Christ SM, Schettle M, Seiler A, Guckenberger M, Blum D, Andratschke N, et al. Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy. Clin Transl Radiat Oncol. 2021;30:26\u201330.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2547_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/0284186X.2017.1324638","volume":"56","author":"LK Rautakorpi","year":"2017","unstructured":"Rautakorpi LK, M\u00e4kel\u00e4 JM, Seyednasrollah F, Hammais AM, Laitinen T, Hirvonen OM, et al. Assessing the utilization of radiotherapy near end of life at a Finnish University Hospital: a retrospective cohort study. Acta Oncol. 2017;56:1265\u201371.","journal-title":"Acta Oncol"},{"key":"2547_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12904-019-0415-8","volume":"18","author":"SY Wu","year":"2019","unstructured":"Wu SY, Singer L, Boreta L, Garcia MA, Fogh SE, Braunstein SE. Palliative radiotherapy near the end of life. BMC Palliat Care. 2019;18:29.","journal-title":"BMC Palliat Care"},{"key":"2547_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.radonc.2017.09.016","volume":"125","author":"KR Park","year":"2017","unstructured":"Park KR, Lee CG, Tseng YD, Liao JJ, Reddy S, Bruera E, et al. Palliative radiation therapy in the last 30 days of life: a systematic review. Radiother Oncol. 2017;125:193\u20139.","journal-title":"Radiother Oncol"},{"key":"2547_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.radonc.2015.03.023","volume":"115","author":"K Spencer","year":"2015","unstructured":"Spencer K, Morris E, Dugdale E, Newsham A, Sebag-Montefiore D, Turner R, et al. 30 day mortality in adult palliative radiotherapy\u2013a retrospective population based study of 14,972 treatment episodes. Radiother Oncol. 2015;115:264\u201371.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02547-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02547-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02547-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:04:15Z","timestamp":1730462655000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02547-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2547"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02547-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As a retrospective quality of care analysis, no approval from the Regional Committee for Medical and Health Research Ethics (REK Nord) was necessary. This research project was carried out according to our institutions\u2019 guidelines and with permission to access the patients\u2019 data. Written informed consent was received from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}